Zydus Lifesciences Sees Significant Open Interest Surge Amid Bullish Momentum

Open Interest and Volume Dynamics

The latest data reveals that Zydus Lifesciences’ open interest (OI) in derivatives jumped by 2,457 contracts, a 14.73% increase from the previous figure of 16,676 to 19,133. This notable rise in OI was accompanied by a volume of 19,809 contracts, indicating robust trading activity in the futures and options segments.

In monetary terms, the futures segment recorded a value of approximately ₹39,204.39 lakhs, while the options segment exhibited an exceptionally high notional value of ₹13,260.70 crores. The combined derivatives turnover stood at ₹40,637.99 lakhs, underscoring the substantial liquidity and interest in Zydus Lifesciences’ contracts.

Price Performance and Moving Averages

On the price front, Zydus Lifesciences has demonstrated resilience and strength. The stock touched an intraday high of ₹962.90, marking a 3.55% gain on the day. Over the last two trading sessions, it has delivered a cumulative return of 2.56%, outperforming its Pharmaceuticals & Biotechnology sector by 0.74% and the Sensex, which declined by 0.82% on the same day.

Technically, the stock is trading above all key moving averages — 5-day, 20-day, 50-day, 100-day, and 200-day — signalling a sustained uptrend and positive investor sentiment. This technical strength aligns with the increased open interest, suggesting that market participants are positioning for further upside.

Investor Participation and Liquidity Considerations

Despite the bullish derivatives activity, delivery volumes have seen a decline. On 22 Apr 2026, the delivery volume was recorded at 1.45 lakh shares, down by 37.86% compared to the five-day average delivery volume. This indicates that while speculative interest in derivatives is rising, actual investor participation in the cash segment has moderated.

Liquidity remains adequate for sizeable trades, with the stock’s average traded value supporting trade sizes up to ₹0.83 crore based on 2% of the five-day average traded value. This liquidity profile favours active traders and institutional participants looking to capitalise on the stock’s momentum.

Market Positioning and Directional Bets

The surge in open interest alongside rising prices and volumes suggests that traders are increasingly bullish on Zydus Lifesciences. The 14.73% increase in OI indicates fresh positions being built rather than existing ones being squared off, which often points to directional conviction.

Given the stock’s current underlying value of ₹953 and its recent intraday high near ₹963, market participants appear to be betting on continued appreciation. The derivatives market activity, especially the substantial options notional value, hints at strategic positioning possibly involving call options or futures contracts to leverage anticipated gains.

However, the falling delivery volume signals some caution among long-term investors, who may be booking profits or awaiting clearer signals before committing further capital in the cash segment. This divergence between derivatives and cash market activity is not uncommon during phases of speculative interest or near-term event anticipation.

Mojo Score and Analyst Ratings

Zydus Lifesciences currently holds a Mojo Score of 48.0, categorised as a Sell rating, a downgrade from its previous Hold status as of 01 Dec 2025. This reflects a cautious stance from analysts despite the recent positive price action and derivatives interest. The mid-cap pharmaceutical company’s market capitalisation stands at ₹94,702 crore, placing it solidly in the mid-cap segment.

The downgrade may be influenced by broader sectoral challenges or valuation concerns, which investors should weigh against the short-term bullish signals from derivatives markets. The stock’s outperformance relative to its sector and the Sensex, however, indicates pockets of strength that could be exploited by nimble traders.

Implications for Investors and Traders

The current derivatives market activity in Zydus Lifesciences offers valuable insights for investors and traders alike. The rising open interest and volume, coupled with price strength, suggest that short-term momentum could continue, presenting opportunities for tactical trades.

However, the Mojo Grade downgrade to Sell and the decline in delivery volumes caution against overexuberance. Long-term investors should consider the broader fundamentals and sector outlook before increasing exposure, while traders may look to capitalise on volatility and directional bets in the derivatives space.

Monitoring open interest trends alongside price action will be crucial in the coming sessions to gauge whether the bullish sentiment sustains or if profit-taking pressures emerge.

Sector and Market Context

Within the Pharmaceuticals & Biotechnology sector, Zydus Lifesciences’ recent outperformance is noteworthy, especially as the sector itself posted a modest 1.63% gain compared to the broader Sensex decline. This relative strength highlights the company’s potential to attract investor interest amid sectoral headwinds.

As a mid-cap stock with a sizeable market capitalisation, Zydus Lifesciences remains a key player in the industry, but its current Mojo Score and analyst sentiment suggest that investors should remain selective and vigilant.

Conclusion

The sharp increase in open interest and robust derivatives turnover in Zydus Lifesciences signals a growing bullish bias among market participants. Supported by positive price momentum and technical strength, the stock is attracting speculative interest despite a cautious analyst outlook and reduced delivery volumes.

Investors and traders should balance these factors carefully, leveraging derivatives activity as a guide to near-term sentiment while considering fundamental and sectoral dynamics for longer-term decisions.

Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →